Skip to main content

USANS - February 2014

By
Just catching up on some recently published USAN statements.

USAN Research Code InChIKey (Parent) Drug Class Therapeutic class Target
asvasiran-sodium

ALN-RSV01

 n/a RNAi therapeutic n/a
beclabuvir

BMS-791325

 ZTTKEBYSXUCBSE-VSBZUFFNSA-N synthetic small molecule therapeutic HCV NS5B polymerase
benzhydrocodone, benzhydrocodone-hydrochloride
KP-201
 VPMRSLWWUXNYRY-PJCFOSJUSA-N natural product derived small molecule therapeutic Opioid receptors
bradanicline, bradanicline-hydrochloride

TC-5619

 OXKRFEWMSWPKKV-GHTZIAJQSA-N synthetic small molecule therapeutic alpha-7 nicotinic acetylcholine receptor
briciclib, briciclib-sodium

ON-014185

 LXENKEWVEVKKGV-BQYQJAHWSA-N synthetic small molecule therapeutic n/a
ceritinib

NVP-LDK378-NX

 VERWOWGGCGHDQE-UHFFFAOYSA-N synthetic small molecule therapeutic ALK
dasabuvir

ABT-333

 NBRBXGKOEOGLOI-UHFFFAOYSA-N synthetic small molecule therapeutic HCV NS5B polymerase
defactinib, defactinib-hydrochloride

VS-6063

 FWLMVFUGMHIOAA-UHFFFAOYSA-N synthetic small molecule therapeutic FAK
dianhydrogalactitol

VAL-083, NSC-1323313

 AAFJXZWCNVJTMK-UHFFFAOYSA-N synthetic small molecule therapeutic DNA
dinutuximab
n/a
 n/a monoclonal antibody therapeutic GD2
diridavumab

CR-6261

 n/a monoclonal antibody therapeutic haemagglutinin
encenicline, encenicline-hydrochloride

EVP-6124

 SSRDSYXGYPJKRR-ZDUSSCGKSA-N synthetic small molecule therapeutic alpha-7 nicotinic acetylcholine receptor
esuberaprost, esuberaprost-sodium


APS-314d, BPS-314d

 CTPOHARTNNSRSR-NOQAJONNSA-N synthetic small molecule therapeutic IP1 receptor
filociclovir


MBX-400

 KMUNHOKTIVSFRA-KXFIGUGUSA-N synthetic small molecule therapeutic CMV DNA polymerase
fosdagrocorat

PF-04171327

 n/a synthetic small molecule therapeutic GR
gedatolisib

PF-05212384, PKI-587

 DWZAEMINVBZMHQ-UHFFFAOYSA-N synthetic small molecule therapeutic PI3K & mTOR
glasdegib

PF-04449913

 SFNSLLSYNZWZQG-VQIMIIECSA-N synthetic small molecule therapeutic smoothened
indoximod
D-1MT
 n/a natural product derived small molecule therapeutic IDO
latiglutenase

ALV-003

 n/a enzyme therapeutic n/a
lulizumab-pegol BMS-931699

 n/a monoclonal antibody therapeutic CD28
ombitasvir

ABT-267

 PIDFDZJZLOTZTM-KHVQSSSXSA-N synthetic small molecule therapeutic HCV NS5a
omega-3-carboxylic-acids
n/a
 n/a natural product derived small molecule therapeutic n/a
peficitinib

ASP-015K

 DREIJXJRTLTGJC-UHFFFAOYSA-N synthetic small molecule therapeutic JAK
pegargiminase
n/a
 n/a enzyme therapeutic n/a
pembrolizumab
n/a
 n/a monoclonal antibody therapeutic Programmed cell death 1 (PDCD1)
polmacoxib

CG-100649

 IJWPAFMIFNSIGD-UHFFFAOYSA-N synthetic small molecule therapeutic COX-2
sarolaner

PF-6450567

 FLEFKKUZMDEUIP-QFIPXVFZSA-N synthetic small molecule therapeutic n/a
transcrocetinate-sodium
n/a
 n/a natural product derived small molecule radiation sensitizer n/a
uprosertib

GSK-2141795C

 AXTAPYRUEKNRBA-JTQLQIEISA-N synthetic small molecule therapeutic AKT1
venetoclax

ABT-199

 LQBVNQSMGBZMKD-UHFFFAOYSA-N synthetic small molecule therapeutic BCL-2

Comments

Post a Comment

Popular posts from this blog

ChEMBL 34 is out!

By
We are delighted to announce the release of ChEMBL 34, which includes a full update to drug and clinical candidate drug data. This version of the database, prepared on 28/03/2024 contains:         2,431,025 compounds (of which 2,409,270 have mol files)         3,106,257 compound records (non-unique compounds)         20,772,701 activities         1,644,390 assays         15,598 targets         89,892 documents Data can be downloaded from the ChEMBL FTP site:  https://ftp.ebi.ac.uk/pub/databases/chembl/ChEMBLdb/releases/chembl_34/ Please see ChEMBL_34 release notes for full details of all changes in this release:  https://ftp.ebi.ac.uk/pub/databases/chembl/ChEMBLdb/releases/chembl_34/chembl_34_release_notes.txt New Data Sources European Medicines Agency (src_id = 66): European Medicines Agency's data correspond to EMA drugs prior to 20 January 2023 (excluding vaccines). 71 out of the 882 newly added EMA drugs are only authorised by EMA, rather than from other regulatory bodies e.g.
Post a Comment
Read more

New SureChEMBL announcement

By
(Generated with DALL-E 3 ∙ 30 October 2023 at 1:48 pm) We have some very exciting news to report: the new SureChEMBL is now available! Hooray! What is SureChEMBL, you may ask. Good question! In our portfolio of chemical biology services, alongside our established database of bioactivity data for drug-like molecules ChEMBL , our dictionary of annotated small molecule entities ChEBI , and our compound cross-referencing system UniChem , we also deliver a database of annotated patents! Almost 10 years ago , EMBL-EBI acquired the SureChem system of chemically annotated patents and made this freely accessible in the public domain as SureChEMBL. Since then, our team has continued to maintain and deliver SureChEMBL. However, this has become increasingly challenging due to the complexities of the underlying codebase. We were awarded a Wellcome Trust grant in 2021 to completely overhaul SureChEMBL, with a new UI, backend infrastructure, and new f
Post a Comment
Read more

Accessing SureChEMBL data in bulk

By
It is the peak of the summer (at least in this hemisphere) and many of our readers/users will be on holiday, perhaps on an island enjoying the sea. Luckily, for the rest of us there is still the 'sea' of SureChEMBL data that awaits to be enjoyed and explored for hidden 'treasures' (let me know if I pushed this analogy too far). See here and  here for a reminder of SureChEMBL is and what it does.  This wealth of (big) data can be accessed via the SureChEMBL interface , where users can submit quite sophisticated and granular queries by combining: i) Lucene fields against full-text and bibliographic metadata and ii) advanced structure query features against the annotated compound corpus. Examples of such queries will be the topic of a future post. Once the search results are back, users can browse through and export the chemistry from the patent(s) of interest. In addition to this functionality, we've been receiving user requests for  local (behind the
Post a Comment
Read more

New Drug Approvals - Pt. XVII - Telavancin (Vibativ)

By jpo
The latest new drug approval, on 11th September 2009 was Telavancin - which was approved for the treatment of adults with complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive bacteria , including Staphylococcus aureus , both methicillin-resistant (MRSA) and methicillin-susceptible (MSSA) strains. Telavancin is also active against Streptococcus pyogenes , Streptococcus agalactiae , Streptococcus anginosus group (includes S. anginosus, S. intermedius and S. constellatus ) and Enterococcus faecalis (vancomycin susceptible isolates only). Telavancin is a semisynthetic derivative of Vancomycin. Vancomycin itself is a natural product drug, isolated originally from soil samples in Borneo, and is produced by controlled fermentation of Amycolatopsis orientalis - a member of the Actinobacteria . Telavancin has a dual mechanism of action, firstly it inhibits bacterial cell wall synthesis by interfering with the polymerization and cross-linking of peptid
Post a Comment
Read more

A python client for accessing ChEMBL web services

By
Motivation The CheMBL Web Services provide simple reliable programmatic access to the data stored in ChEMBL database. RESTful API approaches are quite easy to master in most languages but still require writing a few lines of code. Additionally, it can be a challenging task to write a nontrivial application using REST without any examples. These factors were the motivation for us to write a small client library for accessing web services from Python. Why Python? We choose this language because Python has become extremely popular (and still growing in use) in scientific applications; there are several Open Source chemical toolkits available in this language, and so the wealth of ChEMBL resources and functionality of those toolkits can be easily combined. Moreover, Python is a very web-friendly language and we wanted to show how easy complex resource acquisition can be expressed in Python. Reinventing the wheel? There are already some libraries providing access to ChEMBL d
1 comment
Read more